Use of embolic protection devices during saphenous vein graft (SVG) interventions is associated with an increase in procedural complications without corresponding improvements in clinical outcomes for ...

Please provide your email address to receive an email when new articles are posted on . Routine cerebral embolic protection did not reduce stroke in patients undergoing transcatheter aortic valve ...

CHICAGO, IL—Cerebral embolic protection devices are infrequently used during transcatheter aortic valve implantation procedures in the United States, and new data suggest their use does not appear to ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — In PROTECTED TAVR, the largest-ever randomized trial of transcatheter aortic valve replacement, ...

WASHINGTON, DC — Are surrogate end points enough to recommend a treatment that seems safe but hasn't "worked" by clinical-trial standards, but many agree ought to work? A pair of catheter-delivered ...

A multicenter EPIC (FiberNet Embolic Protection System in Carotid Artery Stenting Trial) study found that the FiberNet Embolic Protection System had a 97.5 percent success rate when used in patients ...

WASHINGTON -- An embolic protection device deployed during transcatheter aortic valve replacement (TAVR) caught plenty of material but without any impact on subclinical or clinical outcomes, the ...

Dublin, Nov. 12, 2021 (GLOBE NEWSWIRE) -- The "Peripheral Embolic Protection Devices (Cardiovascular Devices) - Medical Devices Pipeline Product Landscape, 2021" report has been added to ...

United States Embolic Protection Device Market is expected to reach US$ 650 million by 2033 from US$ 360 million in 2024, with a CAGR of 6.96% from 2025 to 2033. Rising cardiovascular operations, ...

The recall was initiated following reports of 9 device malfunctions. Cardiovascular Systems Inc. has issued a voluntary recall of unused WIRION ® Embolic Protection systems due to complaints of filter ...

ST. PAUL, Minn.--(BUSINESS WIRE)-- Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients ...

Transcatheter aortic valve replacement (TAVR) is revolutionizing the treatment of aortic valve stenosis, offering a minimally invasive option for patients suffering from this heart condition. However, ...